✨ Free AI Report
Cadrenal Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Cadrenal Therapeutics, Inc.
Company Research

Cadrenal Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Cadrenal Therapeutics is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. The company targets orphan indications with narrow therapeutic windows w...

Analyst-debate audio for Cadrenal Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Cadrenal Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

High-risk, high-reward clinical-stage biotech with differentiated mechanisms targeting orphan thrombotic diseases, near-term...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Anticoagulation & Rare Cardiovascular Therapeutics
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Cadrenal Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Cadrenal Therapeutics, Inc. Overview

Pro stress-test →

Cadrenal Therapeutics is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. The company targets orphan indications with narrow therapeutic windows where existing anticoagulants fail, representing a significant unmet medical need in rare cardiovascular and immune disorders.

Strategic Profile

Pro stress-test →

Cadrenal develops novel and differentiated biopharmaceutical products to bridge essential gaps in currently available anticoagulation therapeutics. The company's 12-LOX inhibitor portfolio represents a differentiated platform approach across a range of thrombotic and inflammatory conditions, with both acute and chronic potential applications.

Competitive Landscape

Pro stress-test →

Existing treatments such as warfarin and DOACs (Eliquis, Xarelto) often do not meet the needs of patients with orphan cardiovascular conditions, creating an addressable market gap. Cadrenal's tecarfarin and 12-LOX inhibitors target specific high-risk patient populations abandoned by conventional anticoagulants, differentiating it from large-cap pharma competitors focused on broader markets.

Industry Context

Cadrenal Therapeutics, Inc. operates in Biopharmaceuticals - Anticoagulation & Rare Cardiovascular Therapeutics.

Key facts

Headquarters: Ponte Vedra, US · Revenue: $0 · Market cap: $12.81M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Cadrenal Therapeutics, Inc..

  • Phase 2 data for CAD-1005 in heparin-induced thrombocytopenia demonstrated a reduction in thrombotic events on a background of standard anticoagulants.
  • The broader pipeline includes tecarfarin (Phase 3-ready vitamin K antagonist) and frunexian (parenteral Factor XIa inhibitor for acute hospital settings).
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • March 2026End-of-Phase 2 meeting scheduled for CAD-1005 in heparin-induced thrombocytopenia
  • March 2026Expanded pipeline with acquisition of selective 12-LOX inhibitors including oral candidates
  • +1 moreTrack every material event for Cadrenal Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Cadrenal Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

WarfarinTraditional oral anticoagulant with narrow therapeutic window→Eliquis (apixaban)DOAC with limited efficacy in kidney disease patients→Xarelto (rivaroxaban)DOAC with limited efficacy in kidney disease patients→

Compare Cadrenal Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Cadrenal Therapeutics, Inc. operates in Biopharmaceuticals - Anticoagulation & Rare Cardiovascular Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Anticoagulation & Rare Cardiovascular Therapeutics research →
NEW · MCP server

Ask your AI assistant about Cadrenal Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Cadrenal Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Cadrenal Therapeutics, Inc. do this quarter?”
“Is Cadrenal Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Cadrenal Therapeutics, Inc. do?+
Cadrenal Therapeutics is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. The company targets orphan indications with narrow therapeutic windows w...
What is Cadrenal Therapeutics, Inc.'s Cyborg Score?+
Cadrenal Therapeutics, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Cadrenal Therapeutics, Inc.'s main competitors?+
Named competitors include Warfarin, Eliquis (apixaban), Xarelto (rivaroxaban). The full competitive landscape is in the AskCyborg report.
How can I get the full Cadrenal Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Cadrenal Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Cadrenal Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.